BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shutinoski B, Hakimi M, Harmsen IE, Lunn M, Rocha J, Lengacher N, Zhou YY, Khan J, Nguyen A, Hake-Volling Q, El-Kodsi D, Li J, Alikashani A, Beauchamp C, Majithia J, Coombs K, Shimshek D, Marcogliese PC, Park DS, Rioux JD, Philpott DJ, Woulfe JM, Hayley S, Sad S, Tomlinson JJ, Brown EG, Schlossmacher MG. Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Sci Transl Med 2019;11:eaas9292. [PMID: 31554740 DOI: 10.1126/scitranslmed.aas9292] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 22.5] [Reference Citation Analysis]
Number Citing Articles
1 Li J, Mestre TA, Mollenhauer B, Frasier M, Tomlinson JJ, Trenkwalder C, Ramsay T, Manuel D, Schlossmacher MG. Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination. npj Parkinsons Dis 2022;8:94. [DOI: 10.1038/s41531-022-00360-5] [Reference Citation Analysis]
2 Gate D. New Perspectives on Immune Involvement in Parkinson’s Disease Pathogenesis. JPD 2022;12:S5-S11. [DOI: 10.3233/jpd-223240] [Reference Citation Analysis]
3 Giachino C, Tirolo C, Caniglia S, Serapide MF, L’episcopo F, Bertoli F, Giuliano C, Mearelli M, Jakobi M, Schneiderhan-marra N, Deleidi M, Marchetti B. LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration.. [DOI: 10.1101/2022.09.01.505977] [Reference Citation Analysis]
4 Weindel CG, Martinez EL, Zhao X, Mabry CJ, Bell SL, Vail KJ, Coleman AK, VanPortfliet JJ, Zhao B, Wagner AR, Azam S, Scott HM, Li P, West AP, Karpac J, Patrick KL, Watson RO. Mitochondrial ROS promotes susceptibility to infection via gasdermin D-mediated necroptosis. Cell 2022;185:3214-3231.e23. [PMID: 35907404 DOI: 10.1016/j.cell.2022.06.038] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Tsafaras G, Baekelandt V. The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. Neurobiol Dis 2022;172:105806. [PMID: 35781002 DOI: 10.1016/j.nbd.2022.105806] [Reference Citation Analysis]
6 Zhang M, Li C, Ren J, Wang H, Yi F, Wu J, Tang Y. The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson’s Disease. Front Aging Neurosci 2022;14:909303. [DOI: 10.3389/fnagi.2022.909303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Parmasad JA, Ricke KM, Stykel MG, Buchner-duby B, Lian E, Nguyen B, Lengacher NA, Geertsma HM, Bruce A, Callaghan SM, Joselin A, Tomlinson JJ, Schlossmacher MG, Stanford WL, Brundin P, Ryan SD, Rousseaux MW. Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy.. [DOI: 10.1101/2022.05.02.490309] [Reference Citation Analysis]
8 Mamais A, Kaganovich A, Harvey K. Convergence of signalling pathways in innate immune responses and genetic formof Parkinson’s disease. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105721] [Reference Citation Analysis]
9 Russo I, Bubacco L, Greggio E. LRRK2 as a target for modulating immune system responses. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105724] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Scoggin K, Lynch R, Gupta J, Nagarajan A, Sheffield M, Elsaadi A, Bowden C, Aminian M, Peterson A, Adams LG, Kirby M, Threadgill DW, Andrews-Polymenis HL. Genetic background influences survival of infections with Salmonella enterica serovar Typhimurium in the Collaborative Cross. PLoS Genet 2022;18:e1010075. [PMID: 35417454 DOI: 10.1371/journal.pgen.1010075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ahmadi Rastegar D, Hughes LP, Perera G, Keshiya S, Zhong S, Gao J, Halliday GM, Schüle B, Dzamko N. Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinsons Dis 2022;8:34. [PMID: 35347144 DOI: 10.1038/s41531-022-00297-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kozina E, Byrne M, Smeyne RJ. Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson's disease. NPJ Parkinsons Dis 2022;8:24. [PMID: 35292674 DOI: 10.1038/s41531-022-00289-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol 2022. [PMID: 35246670 DOI: 10.1038/s41577-022-00684-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 32.0] [Reference Citation Analysis]
14 Mercier V, Boucher G, Devost D, Bourque K, Alikashani A, Beauchamp C, Bitton A, Foisy S, Goyette P, Charron G, Hébert TE, Rioux JD. IBD-associated G protein-coupled receptor 65 variant compromises signalling and impairs key functions involved in inflammation. Cell Signal 2022;:110294. [PMID: 35218908 DOI: 10.1016/j.cellsig.2022.110294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Linard M, Ravier A, Mougué L, Grgurina I, Boutillier AL, Foubert-Samier A, Blanc F, Helmer C. Infectious Agents as Potential Drivers of α-Synucleinopathies. Mov Disord 2022. [PMID: 35040520 DOI: 10.1002/mds.28925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Weindel CG, Zhao X, Martinez E, Bell SL, Vail KJ, Coleman AK, Vanportfliet JJ, Zhao B, Mabry CJ, Li P, Phillip West A, Karpac J, Patrick KL, Watson RO. Mitochondrial dysfunction promotes alternative gasdermin D-mediated inflammatory cell death and susceptibility to infection.. [DOI: 10.1101/2021.11.18.469014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Lipoldová M, Demant P. Gene-Specific Sex Effects on Susceptibility to Infectious Diseases. Front Immunol 2021;12:712688. [PMID: 34721380 DOI: 10.3389/fimmu.2021.712688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Axtman AD. Characterizing the role of the dark kinome in neurodegenerative disease - A mini review. Biochim Biophys Acta Gen Subj 2021;1865:130014. [PMID: 34547390 DOI: 10.1016/j.bbagen.2021.130014] [Reference Citation Analysis]
19 Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, Hirst WD, El-Agnaf O, Mollenhauer B, Lansbury P, Outeiro TF. Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. NPJ Parkinsons Dis 2021;7:65. [PMID: 34312398 DOI: 10.1038/s41531-021-00203-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 18.0] [Reference Citation Analysis]
20 Provenzano F, Deleidi M. Reassessing neurodegenerative disease: immune protection pathways and antagonistic pleiotropy. Trends Neurosci 2021:S0166-2236(21)00118-1. [PMID: 34284880 DOI: 10.1016/j.tins.2021.06.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Tokarew JM, El-Kodsi DN, Lengacher NA, Fehr TK, Nguyen AP, Shutinoski B, O'Nuallain B, Jin M, Khan JM, Ng ACH, Li J, Jiang Q, Zhang M, Wang L, Sengupta R, Barber KR, Tran A, Im DS, Callaghan S, Park DS, Zandee S, Dong X, Scherzer CR, Prat A, Tsai EC, Takanashi M, Hattori N, Chan JA, Zecca L, West AB, Holmgren A, Puente L, Shaw GS, Toth G, Woulfe JM, Taylor P, Tomlinson JJ, Schlossmacher MG. Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. Acta Neuropathol 2021;141:725-54. [PMID: 33694021 DOI: 10.1007/s00401-021-02285-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
22 Dallmann-sauer M, Xu YZ, da Costa ALF, Tao S, Correa-macedo W, Manry J, Abel L, Alcaïs A, Cobat A, Fava VM, Probst CM, Mira MT, Schurr E. Early onset leprosy reveals a joint effect of LRRK2 and NOD2 variants.. [DOI: 10.1101/2021.03.25.21253623] [Reference Citation Analysis]
23 Patrick KL, Watson RO. Mitochondria: Powering the Innate Immune Response to Mycobacterium tuberculosis Infection. Infect Immun 2021;89:e00687-20. [PMID: 33558322 DOI: 10.1128/IAI.00687-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
24 Lorente-Picón M, Laguna A. New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota. Biomolecules 2021;11:433. [PMID: 33804226 DOI: 10.3390/biom11030433] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
25 Sardi SP, Baptista MA. Parkinson's disease: Genetic-driven therapeutic approaches. Neurotherapeutics in the Era of Translational Medicine 2021. [DOI: 10.1016/b978-0-12-816475-4.00008-2] [Reference Citation Analysis]
26 Mahalakshmi AM, Ray B, Tuladhar S, Bhat A, Paneyala S, Patteswari D, Sakharkar MK, Hamdan H, Ojcius DM, Bolla SR, Essa MM, Chidambaram SB, Qoronfleh MW. Does COVID-19 contribute to development of neurological disease? Immun Inflamm Dis 2021;9:48-58. [PMID: 33332737 DOI: 10.1002/iid3.387] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
27 Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. Mov Disord 2021;36:25-36. [PMID: 33314312 DOI: 10.1002/mds.28411] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
28 Tan JSY, Chao YX, Rötzschke O, Tan EK. New Insights into Immune-Mediated Mechanisms in Parkinson's Disease. Int J Mol Sci 2020;21:E9302. [PMID: 33291304 DOI: 10.3390/ijms21239302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
29 Li J, Mestre TA, Mollenhauer B, Frasier M, Tomlinson JJ, Trenkwalder C, Ramsay T, Manuel D, Schlossmacher MG. Evaluation of the PREDIGT Score in Discriminating Parkinson Disease from Neurological Health.. [DOI: 10.1101/2020.11.29.20240028] [Reference Citation Analysis]
30 Tokarew JM, El-kodsi DN, Lengacher NA, Fehr TK, Nguyen AP, Shutinoski B, O’nuallain B, Jin M, Khan JM, Ng ACH, Li J, Jiang Q, Zhang M, Wang L, Sengupta R, Barber KR, Tran A, Zandee S, Dong X, Scherzer CR, Prat A, Tsai E, Takanashi M, Hattori N, Chan JA, Zecca L, West AB, Holmgren A, Puente L, Shaw GS, Toth G, Woulfe JM, Taylor P, Tomlinson JJ, Schlossmacher MG. Age-Associated Insolubility of Parkin in Human Midbrain is Linked to Redox Balance and Sequestration of Reactive Dopamine Metabolites.. [DOI: 10.1101/2020.11.20.392175] [Reference Citation Analysis]
31 Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G. Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease. Int J Mol Sci 2020;21:E8421. [PMID: 33182554 DOI: 10.3390/ijms21228421] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 26.5] [Reference Citation Analysis]
32 Menozzi E, Macnaughtan J, Schapira AHV. LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture? Mov Disord 2021;36:71-5. [PMID: 33107648 DOI: 10.1002/mds.28347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 von Linstow CU, Gan-Or Z, Brundin P. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. Transl Neurodegener 2020;9:39. [PMID: 33066808 DOI: 10.1186/s40035-020-00218-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
34 Liu Z, Xu E, Zhao HT, Cole T, West AB. LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes. EMBO J 2020;39:e104862. [PMID: 32853409 DOI: 10.15252/embj.2020104862] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 12.5] [Reference Citation Analysis]
35 Padmanabhan S, Fiske BK, Baptista MAS. The Michael J. Fox Foundation's Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease. Cells 2020;9:E1878. [PMID: 32796584 DOI: 10.3390/cells9081878] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Herbst S, Campbell P, Harvey J, Bernard EM, Papayannopoulos V, Wood NW, Morris HR, Gutierrez MG. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO J 2020;39:e104494. [PMID: 32643832 DOI: 10.15252/embj.2020104494] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 26.5] [Reference Citation Analysis]
37 Wallings RL, Herrick MK, Tansey MG. LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson's. Front Neurosci 2020;14:443. [PMID: 32508566 DOI: 10.3389/fnins.2020.00443] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
38 Xu E, Boddu R, Abdelmotilib HA, Kelly K, Sokratian A, Harms AS, Schonhoff AM, Bryant N, Harmsen IE, Schlossmacher MG, Chandra S, Krendelshchikova V, Liu Z, West AB. Pathologic α-Synuclein Species Activate LRRK2 in Pro-Inflammatory Monocyte and Macrophage Responses.. [DOI: 10.1101/2020.05.04.077065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Cabezudo D, Baekelandt V, Lobbestael E. Multiple-Hit Hypothesis in Parkinson's Disease: LRRK2 and Inflammation. Front Neurosci 2020;14:376. [PMID: 32410948 DOI: 10.3389/fnins.2020.00376] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
40 Lippi A, Domingues R, Setz C, Outeiro TF, Krisko A. SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration. Mov Disord 2020;35:716-20. [PMID: 32291797 DOI: 10.1002/mds.28084] [Cited by in Crossref: 83] [Cited by in F6Publishing: 89] [Article Influence: 41.5] [Reference Citation Analysis]
41 Kuwahara T, Iwatsubo T. The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System. Front Neurosci 2020;14:227. [PMID: 32256311 DOI: 10.3389/fnins.2020.00227] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
42 Ahmadi Rastegar D, Dzamko N. Leucine Rich Repeat Kinase 2 and Innate Immunity. Front Neurosci 2020;14:193. [PMID: 32210756 DOI: 10.3389/fnins.2020.00193] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
43 Wallings RL, Tansey MG. LRRK2 regulation of immune-pathways and inflammatory disease. Biochem Soc Trans 2019;47:1581-95. [PMID: 31769472 DOI: 10.1042/BST20180463] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 28.0] [Reference Citation Analysis]
44 Taylor M, Alessi DR. Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease. Curr Opin Cell Biol 2020;63:102-13. [PMID: 32036294 DOI: 10.1016/j.ceb.2020.01.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 41] [Article Influence: 29.5] [Reference Citation Analysis]
45 Liu Z, Xu E, Zhao HT, Cole T, West AB. LRRK2 and Rab10 Coordinate Macropinocytosis to Mediate Immunological Responses in Phagocytes.. [DOI: 10.1101/2020.01.30.926840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 [DOI: 10.1101/2020.02.19.953034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]